1-4 of 4
Secundino Ferrer, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Jose A Garcia-Marco, MD, PhD, Javier Lopez-Jimenez, MD, Secundino Ferrer, MD, Pilar Giraldo, MD, PhD, Eva González-Barca, MD, Belen Navarro, MD, Eulogio Conde, MD, PhD, Marcos González, Jose L. Guzman, MD, Ernesto Perez, MD, Javier De la Serna, MD, PhD, Mar Osma, MD, Guillermo Deben, MD, Encarna Monzo, MD, Raquel de Paz, MD, M. Angeles Ruiz, MD, Francisco-Javier Penalver, Isidro Jarque, MD, Helena Bañas, MD, M. Carmen Fernandez, MD, Rafael Martinez, MD, Carmen Burgaleta, MD, Jaime Perez de Oteiza, MD, M.Angeles Andreu, MD, Ana Carral, MD, Inmaculada Fuentes, MD, Eva Donato, MD, Paola Leon, MD, Felix Carbonell, MD, Jose A. Garcia-Vela, MD
Journal: Blood
Blood (2010) 116 (21): 2448.
https://doi.org/10.1182/blood.V116.21.2448.2448
Published: 2010
Journal Articles

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Francesc Bosch, MD, PhD, Pau Abrisqueta, MD, Neus Villamor, MD, PhD, Maria Jose Terol, MD, Josep-Maria Ribera, MD, Eva Gonzalez-Barca, MD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Yolanda Gonzalez, MD, Secundino Ferrer, MD, Felix Carbonell, MD, Lourdes Escoda, MD, Isidro Jarque, MD, Encarnacion Monzo, MD, Ana Muntañola, MD, Olga Salamero, MD, Emili Montserrat, MD
Journal: Blood
Blood (2008) 112 (11): 2097.
https://doi.org/10.1182/blood.V112.11.2097.2097
Published: 2008
Journal Articles

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Francesc Bosch, MD, PhD, Ana Muntañola, MD, Neus Villamor, MD, Maria Jose Terol, MD, Elena Gonzalez-Barca, MD, Josep Maria Ribera, MD, PhD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Felix Carbonell, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Lourdes Escoda, MD, Secundino Ferrer, MD, E. Monzo, MD, Yolanda Gonzalez, MD, Pau Abrisqueta, MD, Olga Salamero, MD, Eva Gine, MD, Emili Montserrat, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 626.
https://doi.org/10.1182/blood.V110.11.626.626
Published: 2007
Journal Articles

Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.

Josep-María Ribera, PhD, Albert Oriol, MD, Mireia Morgades, MD, Eva González-Barca, MD, Pilar Miralles, MD, Armando Lopez-Guillermo, MD, Andres Lopez, MD, Blanca Xicoy, MD, Eugenia Abella, MD, Santiago Gardella, MD, Marta García, MD, Joan Bargay, MD, Katy Perez-Equiza, MD, Javier Briones, MD, Lluis Rodriguez, MD, Mariano Provencio, MD, Lourdes Escoda, MD, Alfons Soler, MD, Miguel Canales, MD, Antonio Asensio, MD, Antonio Romero, MD, Secundino Ferrer, MD, Evarist Feliu, MD
Journal: Blood
Blood (2005) 106 (11): 774.
https://doi.org/10.1182/blood.V106.11.774.774
Published: 2005